Vertaling van "benefit in other " (Nederlands → Frans) :

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

Some epidemiological data suggest that wearing a mask can also be of benefit in other circumstances and should be suggested.
Certaines données épidémiologiques suggèrent que le port d'un masque peut également être profitable dans d'autres circonstances et devrait être conseillé.

Assess whether funding is allocated efficiently, taking into account societal benefits, including those generated by promotion, prevention and care. iv. Evaluate whether coverage is comprehensive and fair in social and private insurancebased systems, on an equal level to that for other conditions, not excluding or discriminating against groups and particularly protecting the most vulnerable.
Assess whether funding is allocated efficiently, taking into account societal benefits, including those generated by promotion, prevention and care.

This release contains forward-looking information about a potential joint venture between Pfizer and Zhejiang Hisun Pharmaceuticals (Hisun) including, among other things, the anticipated benefits there of, that involves substantial risks and uncertainties.
This information contained in this release is as of June 2, 2011, Pfizer assumes no obligation to update forward-looking statements contaiTned in this release as the result of new information or future events or developments. This release contains forward-looking information about a potential joint venture between Pfizer and Zhejiang Hisun Pharmaceuticals (Hisun) including, among other things, the anticipated benefits there of, that involves substantial risks and uncertainties.

Studies are underway to review potential anti-cancer benefits in other tumor types.
Des études sont en cours afin de déterminer les bénéfices anticancer potentiels de ce médicament dans d’autres types de tumeurs.

Higher net costs from Other Income & Expense (-0.3 percentage points) were mainly due to the first quarter in the 2009 period benefiting from provision reversals related to launch product inventories.
La hausse des charges nettes d'Autres produits et charges (-0,3 point de pourcentage) résulte principalement de reprises, au premier trimestre 2009, de provisions relatives à des stocks de produits en attente d'homologation.

Studies are underway to review the potential anti-cancer benefits of Zometa in other tumor types.
Des études sont en cours afin de déterminer les avantages potentiels de Zometa dans d’autres types de tumeurs.

Studies are underway to review potential benefits in other tumor types.
Des études sont en cours afin de déterminer les bénéfices anticancer potentiels de ce médicament dans d’autres types de tumeurs.

Higher net costs from Other Income and Expense (–1.1 percentage points) were mainly due to the 2009 period benefiting from provision reversals for launch product inventories.
La hausse d'autres produits et charges (-1,1 point de pourcentage) résulte principalement de reprises, au premier trimestre 2009, de provisions pour stocks de produits lancés.